John Mohr
Chief Tech/Sci/R&D Officer bij SCPHARMACEUTICALS INC.
Actieve functies van John Mohr
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SCPHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 01-05-2018 | - |
Loopbaan van John Mohr
Eerdere bekende functies van John Mohr
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-07-2015 | 01-05-2016 |
| THE MEDICINES COMPANY | Chief Tech/Sci/R&D Officer | 01-03-2015 | 01-06-2015 |
| The University of Texas Medical School At Houston | Corporate Officer/Principal | 01-01-2003 | 01-10-2007 |
Opleiding van John Mohr
| Texas A&M University | Undergraduate Degree |
| University of Houston | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SCPHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
